载脂蛋白 E4 阳性 MCI 患者血浆 MMP-9 水平与向痴呆转化的未来风险：基于阿尔茨海默病神经影像学倡议数据库的研究。

Plasma MMP-9 Levels as the Future Risk of Conversion to Dementia in ApoE4-Positive MCI Patients: Investigation Based on the Alzheimer's Disease Neuroimaging Initiative Database.

机构信息

Yuhei Chiba, 3-9 Fukuura Kanazawa-Ku Yokohama Kanagawa 236-0004, Japan, Telephone: +81-45-787-2667, FAX: +81-45-783-2540, E-mail:

出版信息

J Prev Alzheimers Dis. 2022;9(2):331-337. doi: 10.14283/jpad.2022.19.

DOI:10.14283/jpad.2022.19

PMID:35543007

Abstract

BACKGROUND

Matrix metalloproteinase 9 (MMP-9) has been reported to be correlated with declines in hippocampal volume and cognitive function in ApoE4-positive MCI patients.

OBJECTIVES

The present study was aimed to investigate the effects of plasma matrix MMP-9 on the conversion risk between mild cognitive impairment (MCI) patients with and without ApoE4.

DESIGN AND SETTING

Retrospective observational study using the data extracted from the Alzheimer's Disease Neuroimaging Initiative database.

PARTICIPANTS

We included 211 ApoE4-positive MCI subjects (ApoE4+ MCI) and 184 ApoE4-negative MCI subjects (ApoE4- MCI).

MEASUREMENTS

We obtained demographic and data including plasma MMP-9 levels at baseline and longitudinal changes in Clinical Dementia Rating (CDR) up to 15 years. We compared conversion rates between ApoE4+ MCI and ApoE4- MCI by the Log-rank test and calculated the hazard ratio (HR) for covariates including age, sex, educational attainment, drinking and smoking histories, medications, and plasma MMP-9 levels using a multiple Cox regression analysis of ApoE4+ MCI and ApoE4- MCI.

RESULTS

No significant differences were observed in baseline plasma MMP-9 levels between ApoE4+ MCI and ApoE4- MCI. High plasma MMP-9 levels increased the conversion risk significantly more than low plasma MMP-9 levels (HR, 2.46 [95% CI, 1.31-4.48]) and middle plasma MMP-9 levels (HR, 1.67 [95% CI, 1.04-2.65]) in ApoE4+ MCI, but not in ApoE4- MCI.

CONCLUSION

Plasma MMP-9 would be the risk of the future conversion to dementia in ApoE4+ MCI.

摘要

背景

基质金属蛋白酶 9（MMP-9）已被报道与载脂蛋白 E4 阳性轻度认知障碍（MCI）患者的海马体积和认知功能下降相关。

目的

本研究旨在探讨血浆基质 MMP-9 对有无载脂蛋白 E4 的 MCI 患者之间从轻度认知障碍（MCI）向痴呆转化风险的影响。

设计和设置

使用从阿尔茨海默病神经影像学倡议数据库中提取的数据进行回顾性观察性研究。

参与者

我们纳入了 211 名载脂蛋白 E4 阳性 MCI 患者（ApoE4+ MCI）和 184 名载脂蛋白 E4 阴性 MCI 患者（ApoE4- MCI）。

测量

我们获得了人口统计学数据，包括基线时的血浆 MMP-9 水平和长达 15 年的临床痴呆评定量表（CDR）的纵向变化。我们通过对数秩检验比较了 ApoE4+ MCI 和 ApoE4- MCI 之间的转化率，并使用多 Cox 回归分析计算了包括年龄、性别、教育程度、饮酒和吸烟史、药物和血浆 MMP-9 水平在内的协变量的危险比（HR），用于 ApoE4+ MCI 和 ApoE4- MCI。

结果

ApoE4+ MCI 和 ApoE4- MCI 之间基线血浆 MMP-9 水平无显著差异。高血浆 MMP-9 水平比低血浆 MMP-9 水平（HR，2.46[95%CI，1.31-4.48]）和中血浆 MMP-9 水平（HR，1.67[95%CI，1.04-2.65]）显著增加了 ApoE4+ MCI 的转化风险，但在 ApoE4- MCI 中则没有。